Eli Lilly的新药Lepodisiran在试验中将关键的心脏病风险因素降低了94%。 Eli Lilly's new drug, lepodisiran, reduced a key heart disease risk factor by 94% in trials.

Eli Lilly的实验药物Lepodisiran显示,在中阶段试验中,血脂蛋白(a)的遗传心脏病风险因素显著降低了近94%。 Eli Lilly's experimental drug, lepodisiran, showed a significant reduction in a genetic heart disease risk factor, lipoprotein(a), by nearly 94% in a mid-stage trial. 该药物的开销良好,没有严重不良事件的报告。 The drug was well-tolerated with no serious adverse events reported. 虽然它有效地降低了这一风险因素,但还需要进行更多的审判,以证实它是否减少了心脏病和其他心血管疾病。 While it effectively lowers this risk factor, larger trials are needed to confirm if it reduces heart attacks and other cardiovascular events.